OR WAIT null SECS
May 09, 2024
The CDMO’s Bedford, NH facility will welcome a new isolator filling line—along with twin lyophilizers—as part of a multi-year, $100 million capital investment project.
April 29, 2024
The CDMO’s boost in production will be centered around pharmaceutical products.
April 25, 2024
The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.
The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.
April 09, 2024
The acquisition initiates a long-term agreement with Beacon Therapeutics, highlighted by clinical and commercial AAV production.
March 22, 2024
The purpose for the deal, the CDMO says, is to meet the demand for commercial mammalian contract manufacturing.
March 08, 2024
A proposed Senate bill is intended to protect citizens’ private health and genetic information.
March 07, 2024
The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.
March 04, 2024
The purchase boosts the parties’ sterile liquid manufacturing capabilities.
February 19, 2024
The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.